`
`
`
`Annals of Oncology12 (Suppl. 2): SW1-S114, 2001.
`© 2001 Kluwer Academic Publishers. Printed in the Netherlands.
`
`Chemotherapyand biotherapyin the treatment of neuroendocrine tumours
`
`K. Oberg
`Department ofEndocrine Oncology, Medical Sciences, Internal Medicine, Uppsala University Hospital, Uppsala, Sweden
`
`Summary
`
`The medical treatment of neuroendocrine GEP tumours must
`be based on the growth properties of the tumour. Medical
`treatmentincludes chemotherapy, somatostatin analogues and
`alpha interferons. Chemotherapy has been particularly active
`in patients with high proliferating neuroendocrine tumours
`such as endocrine pancreatic tumours and lung carcinoids.
`Streptozotocin-based combinations including 5-flourouracil
`and doxorubicin have generated partial remissions in 40%—
`60% of the patients giving a median survival of about two
`years in patients with advanced disease. Cisplatinum plus
`etoposide have demonstrated significant antitumoureffects in
`anaplastic endocrine pancreatic tumours and lung carcinoids.
`However, in low proliferating tumours suchasclassical midgut
`carcinoids the response rates with the same combinations of
`cytotoxic agents have only generated short lasting responses
`in less than 10% ofpatients. In these patients, biological treat-
`ment has been of benefit. Alpha interferon at doses of 3-9
`million units three to seven times per week subcutaneously,
`has given biochemical response rates of 50% and significant
`
`tumourreduction in about 15%of patients with long duration,
`up to three years.
`Somatostatin analogues have been widely used in thetreat-
`ment of neuroendocrine gut and pancreatic tumours. The
`currently available somatostatin analogues particularly bind
`somatostatin receptor 2 and 5 and with low affinity also
`receptor subtype 3. Octreotide is registered in most countries
`for the treatmentof patients with carcinoid syndromeandalso
`VIP and glucagon producing tumours. Regular octreotide at
`standard doses of 100-300 pg/day gives symptomatic re-
`sponses in a medium of 60% of patients and biochemical
`responses in up to 70% of patients. Significant tumour re-
`sponses are rare, less than 5%. Long-acting formulations of
`somatostatin analogues have been ofsignificant benefit for the
`patients with similar response rates as for regular formula-
`tions. The quality of life has been significantly improved by
`using the long-acting formulations.
`
`Key words: alpha interferon, lanreotide, octreotide, somatos-
`tatin analogues, streptozotocin
`
`Introduction
`
`The medical treatment of neuroendocrine GEP tumours
`must be based on the growth properties of the tumour.
`Medical treatment includes chemotherapy, somatostatin
`analogues and alpha interferons. Because ofthe rarity
`of these tumours, clinical studies have frequently been
`reported in a very tenious fashion, Furthermore, many
`of the studies do not take into account differencies in
`biological behaviour between classical midgut carci-
`noids and endocrine pancreatic tumours. In addition,
`manycliniciansare still reluctant to treat patients with
`neuroendocrine GEP tumours without clinical symp-
`toms since they have been assigned a good prognosis.
`However, a critical look at the survival data in patients
`with malignant neuroendocrine GEP-tumours showed a
`five-year survival rate of 20% and and average survival
`of two years when liver metastases are present in carci-
`noid tumour patients. For endocrine pancreatic tu-
`mours, the survival data are even worse [1, 2]. Today
`there is no medical treatment for ‘bulky’ disease that
`cures the patient. However, the quality oflife for patients
`with functioning tumours has been significantly improved
`
`by the introduction of biological treatment, in particular
`somatostatin analogues and alphainterferons.
`
`Chemotherapy
`
`Chemotherapy has been considered ‘the gold standard’
`for treatment of most GEP tumours. However,
`it has
`usually been reported in studies involving a limited
`numbers of patients with variable criteria for assessing
`antitumour
`responses. Chemotherapy for endocrine
`pancreatic tumourshas beenofsignificant benefit [3-5].
`Streptozotocin based combinations including 5-flour-
`ouracil (5-FU) and doxorubicin have generated partial
`remissions in 40%-60% ofthe patients, giving a median
`survival of about two years in patients with metastatic
`disease. In contrast to the experience of chemotherapy
`for endocrine pancreatic tumours, classical midgut carci-
`noids have been rather resistant to various combinations
`of chemotherapeutic drugs. Combination chemotherapy
`trials,
`including streptozotocin, 5-FU, cyclophospha-
`mide or doxorubicin has only generated short-lasting
`responses in fewer than 10% of the patients [2, 5, 6].
`
`
`
`
`
`9107‘SZYoue]UOJUoUNIedags[eLlsye/310"speuINofpsoyxo"ouOUUL//:dyYWOpepeopuMog
`
`West-Ward Pharm.
`Exhibit 1025
`Page 001
`
`West-Ward Pharm.
`Exhibit 1025
`Page 001
`
`
`
`SURGERY*
`
`
`
`
`i
`
`Low Prolif.
`
`High Prolif.
`
`eran)ANEPI
`
`112
`
`However, in a subset of carcinoid tumoursin particular
`forgut (lung,
`thymic), cytotoxic agents have produced
`remarkable remissions, in particular a combination of
`cisplatinum and etoposide. That is also true for ana-
`plastic endocrine pancreatic tumoursbut not for highly
`differentiated tumours [8].
`Liver targeted chemotherapy has been reported in
`sometrials where objective responsed have been noticed
`in 60% of the patients with a median duration of 18
`months, in patients receiving embolization + DTIC +
`doxorubicin + 5-FU + streptozotocin [9]. Other trials
`including embolization + doxorubicin have generated
`response rates between 35%-78% with a duration of 17—-
`24 monthswith significantly lowerside-effects.
`Today, chemotherapy should be primarily reserved
`for patients with high proliferation capacity irrespective
`ofthe localisation of the primary tumour(see algorithm,
`Figure 1). The precise level of the proliferation index
`(Ki-67) has not been determined but definitely prolifer-
`ation indices of about 10% and wide spread disease
`might support systemic chemotherapy as a first
`line
`(10, 11].
`
`Biotherapy
`
`Markers (CgA)
`Octreoscan
`
`CT, MRI, PET
`
`Therapy
`a-TFN + SMS
`Embolization £
`
`7
`
`Therapy *
`STZ + SFU, Doxo
`
`Reduction *
`
`Cispl + Etop.
`Other
`
`|
`
`Chemo
`RF
`
`=
`
`Cyotore
`‘Therapy
`
`Tumor Targeted
`Treamment
`
`(MIBG "'Ind-Octr., "¥-DOTA-Octr.)
`
`* NB! SMS could be used during surgery and cytoreduction to facilitate
`the procedure. Can also be used in combination with cytotoxic
`therapy.
`
`
`
`
`
`9107‘SZYue]UOJUoUNIedaqs[eLog18/BJ0"syeuINofpsoyxo-ouOUUR//:d}yYWOpopeojuMog
`
`Biological treatment of neuroendocrine tumoursinclude
`alpha interferons and somatostatin analogues.
`
`Figure |. Neuroendocrine tumors.
`
`Interferon
`
`Alpha interferon was introduced by our group in the
`treatment of carcinoid tumours in 1982, because of its
`ability to stimulate natural killer cell function and to
`control hormone secretion, clinical symptoms and tu-
`mour growth [12]. Since then, more than 400 patients
`have been reported in the literature treated with alpha
`interferon [13-16]. Today recombinant alpha interferon
`are used (Intron, o-interferon 2b and Roferon, «-inter-
`feron 2a). Alpha interferon 2b is the most commonly
`used g-interferon. The applied doses of x-interferon have
`been 3-9 MU 3-7 times/week subcutaneously. The dose
`has to be individually titrated in the patients and as a
`guide-line the leukocyte count should be reduced to 3.0
`x 10°V/I. By using suchtitration the biochemical response
`rate in carcinoid tumour has been reported to be 50%
`and significant tumour reduction 15%. The median du-
`ration response has been 32 months and 35% of the
`patients showed stabilisation of their disease with no
`further tumour growth. Only 15% of the patients con-
`tinued to progress. Survival data from our own center
`and from others, showed improved survival after treat-
`ment with g-interferon in malignant classical midgut
`tumours with a carcinoid syndrome. The median sur-
`vival for patients with malignant carcinoids and liver
`metastases is al our institution more than eight years
`during continuous biotherapy [17]. Also in patients with
`low proliferating endocrine pancreatic tumours, a re-
`sponserate of about 50% have been obtained lasting for
`
`more than two years. The mechanism of action of a-
`interferon is supposed to be a direct effect on the tumour
`cells but also trigging the immunesystem. It is known to
`inhibit
`the cell cycle in G-I
`to S-phase in carcinoid
`tumour cell and it
`inhibits the production of growth
`factor/receptors and other agents secreted by tumour
`cells. It is also known to induce class | antigens on the
`cell surface and thereby attract various responsecells of
`the immunesystem. It is also assumed that a-interferon
`has an anti-angiogenetic effect, which has been explored
`in children treated for multiple hemangiomas.
`Alphainterferon has been combined with somatostatin
`analogues, especially octreotide, with significant poten-
`tiation ofthe clinicaleffect.
`In a group of patients resistant to somatostatin ana-
`logues, the addition of a-interferon (median 5 MU three
`times/week) generated biochemical responses in 77% of
`the patients with 18% complete biochemical remission
`[18]. However, no significant tumour reduction was seen
`in this trial. Theoretical basis for using the combination
`of these two compoundsis based on studies in vitro
`and in vivo in BON-cells, which are neuroendocrine
`differentiated cells. The combination of octreotide and
`a-interferon causes a significant growth inhibition com-
`pared to a single agent. Another recent study from our
`own group in malignant endocrine pancreatic tumour
`resistant to either «-interferon alone, somatostatin ana-
`logue alone or cytotoxic treatment, has generated 35%
`objective tumour reduction and 50% biochemical re-
`
`West-Ward Pharm.
`Exhibit 1025
`Page 002
`
`West-Ward Pharm.
`Exhibit 1025
`Page 002
`
`
`
`sponses, These data are further supported by a recent
`publication from a German group, showing tumour
`reduction in more than 50% of patients receiving the
`combination of «-interferon and somatostatin analogue
`[19]. The adverse effects of a-interferon treatment in-
`clude mainly flu-like symptomsfor the initial 34 days,
`which can be managed by paracetamolor aspirin. More
`severe adverse reaction is the chronic fatigue syndrome
`which occur in about 50% ofthe patients and sometimes
`also give mental depression. Another adverse reaction
`might be induction of autoimmune phenomenon with
`development of anti-nuclear,
`thyroid antibodies and
`sometimes development of thyroid dysfunction. Also
`neutralising antibodies
`to recombinant «-interferon
`might develop to which might abrogate the antitumour
`response.
`Interferon should be used in low proliferating tumours
`with limited tumour burden such as classical midgut
`carcinoids, where it has shown an antiproliferative effect
`(Figure 1). In the future,
`trials of adjuvant treatment
`after surgery with curative intent should be done to
`explore whether a-interferon can prevent the develop-
`ment of metastatic disease later on.
`
`Somatostatin analogues
`
`Somatostatin analogues have been widely used in the
`treatment of neuroendocrine gut- and pancreatic tu-
`mours. They can inhibit the release of peptides from the
`tumours and by that improving the clinical symptoms
`related to these tumours. The currently available soma-
`tostatin analogues are particularly seeing somatostatin
`receptor 2 and 5, and with low affinity also receptor type
`3 [20]. Octreotide is registered in most countries for the
`treatmentof patients with carcinoid syndrome and also
`VIP and glucagon producing tumours. Today a large
`number of patients (more than a thousand) have been
`treated with somatostatin analogues. Regular octreotide
`at standard doses of 100-300 pg/day, give symptomatic
`responses in a median 60% ofthe patients (21]. Bio-
`chemical responses have been obtained in 70% of the
`patients and tumour responses in about 5%. When
`giving high-dose treatment (> 3000 g/day), the symp-
`tomatic and biochemical responses are similar but the
`tumour responses are slightly increased to 11% [22].
`Recently a slow release formulation has been developed
`for octreotide, Sandostatin-LAR, and the patients
`switch from regular octreotide to LAR at doses of 20-
`30 mg intramuscular per month, showing continuing
`biochemical response in more than 80% ofthe patients.
`Similar data has been obtained for a long-acting formu-
`lation of somatuline (lanreotide-PR) given 30 mg every
`two weeks intramuscular, where 50% of the patients
`showed biochemical response and a mean of 3% tumour
`responses. Moreinteresting was the quality oflife evalu-
`ation using QLQ-30, where a significant improvementin
`the quality of life was obtained during treatment with a
`long-acting formulation [23].
`The average survival
`for patients with malignant
`
`113
`
`midgut carcinoids has been estimated at 36 months for
`somatostatin analogue treatment. The side-effects of
`octreotide treatment are generally mild and include fat
`malobsorption and sometimesgall bladder dysfunction
`and gall stones. The long-acting formulation is a real
`advantage for patients just taking one injection every
`three to four weeks, instead of three times/day.
`Somatostatin analogues will be the gold standard for
`management of hormonalclinical symptoms related to
`neuroendocrine GEP tumours for many years. Since
`there are five subtypes of somatostatin receptors, sub-
`type specific analogues might resolve the precise single
`transduction pathway and action from each subtype of
`receptor. It has also been recently shown that there is a
`cross-talk between somatostatin receptors within the
`same cell which can modulate response to a certain
`subtype of somatostatin analogue.
`
`References
`
`1. Goodwin JD. Carcinoid tumors: An analysis of 2837 cases.
`Cancer 1975; 36: 560-9.
`2. Moertel CG. Treatmentof the carcinoid tumor and the malignant
`carcinoid syndrome. J Clin Oncol 1983; I: 727-40.
`3. Moertel CG, Lefkopoulo M, Lipsitz M. Streptozocin-doxorubicin,
`streptozocin fluorouracil, or chlorozotocin in the treatment of
`advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-3.
`4. Eriksson B, Oberg K. An update of the medical treatment of
`malignant endocrine pancreatic tumors. Acta Oncol 1993; 32:
`203-8.
`5. Oberg K. The use of chemotherapyin the managementof neuro-
`endocrine tumours. Endocrinol Metab Clin North Am 1993; 22:
`941-2.
`6. Oberg K, Norheim I, Lundqvist G, Wide L. Cytotoxic treatment
`in patients with malignant carcinoid tumors: Response to strep-
`tozocin — alone or in combination with 5-FU. Acta Oncol 1987;
`26: 429-2,
`7. Moertel CG, Hanley JA. Combination chemotherapy trials in
`metastatic carcinoid tumor and the malignant carcinoid syn-
`drome. CancerClin Trials 1979; 2: 327-4,
`8. Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of
`neuro-endocrine carcinomas with combined etoposide and cis-
`platin. Evidence of major therapeutic activity in the anaplastic
`variants of these neoplasms. Cancer 1991; 68: 227-2.
`9. Hajarizadeh H, Ivancev K, Mueller C etal. Effective palliative
`treatment of metastatic carcinoid tumours with intra-arterial
`chemotherapy/chemoembolisation combined with octreotide ace-
`tate. Am J Surg 1992; 163: 479-3.
`10. Chaudry A, Oberg K, Wilander E. A studyofbiological behaviour
`based on the expression of a proliferating antigen in neuroendo-
`crine tumors of the digestive system. Tumor Biol 1992; 13: 27-5.
`11. Costes V, Marty-Ané C, Piecot MC et al. Typical and atypical
`bronchopulmonary carcinoid tumors: A clinico-pathologic and
`Ki-67 labeling study. Human Pathol 1995; 26: 740-5.
`12. Oberg K, Funa K, Alm G.Effects of leukocyte interferon upon
`clinical symptoms and hormonelevels in patients with midgut
`carcinoid tumors and the carcinoid syndrome. N Engl J Med
`1983; 309: 129-3.
`13, Oberg K, Norheim I, Lind E et al. Treatment of malignant
`carcinoid tumors with human Jeukocyte interferon. Long-term
`results. Cancer Treat Rep 1986; 70: 1297~4.
`14. Biesma B, Willemse PHB, Mulder NH. Recombinantinterferon
`alpha 2b in patients with metastatic apudomas; effect on tumors
`and tumor markers. Br J Cancer 1992; 66: 880-5.
`15. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid
`
`
`
`
`
`910Z‘SZYue]UOJuouNIedaqsTeLiosye/B10°syeuNofpsoyxo-ouOUUE//:dyYWOpopeopuMog
`
`West-Ward Pharm.
`Exhibit 1025
`Page 003
`
`West-Ward Pharm.
`Exhibit 1025
`Page 003
`
`
`
`114
`
`tumor and the malignant carcinoid syndrome with recombinant
`leukocyte A interferon. J Clin Oncol 1989; 7: 865-8.
`Jacobsen MB, Hanssen LE, KolmanskogF et al. The effect of
`interferon a-2b treatment with or without prior hepatic artery
`embolization on clinical response and survival in midgut carci-
`noid patients. Scand J Gastroenterol 1995, 30: 789-6.
`Oberg K, Eriksson B. The role ofinterferons in the management
`of carcinoid tumors. Acta Oncal 1991; 30: 789-6.
`. Tiensuu Janson E, Ahlstrom H, Andersson T, Oberg KE. Octreo-
`tide and interferon alpha: A new combinationfor the treatment of
`malignant carcinoid tumors. Eur J Cancer 1992; 28: 1647a-50a.
`Arnold R. Antiproliferative treatment of metastatic neuroendo-
`crine gastro-enteropancreatic tumors; effect of combination ther-
`apy with octreotide and a-interferon. In M. Mignon, Colombel
`JF (eds): Recent Advancesin the Patophysiology of Inflammatory
`Bowel Diseases and Digestive Endocrine Tumors. Paris: John
`Libbey 1999; 292-5,
`Patel YC, Greenwood MT, Panetta R et al. Mini-review: The
`somatostatin receptor family. Life Sci 1995; 57: 1249-5.
`
`20.
`
`21.
`
`22.
`
`23.
`
`Harris A, Redfern JS. Octreotide treatment of carcinoid syn-
`drome: Analysis of published dose-titration data. Aliment Phar-
`macol Ther 1995; 9: 387-4.
`Imam H, Eriksson B, Lukinius A et al. Induction of apoptosis in
`neuroendocrine tumors of the digestive system during treatment
`with somatostatin analogs. Acta Oncol 1997; 36 (6): 607-4.
`Wymenga ANM, Eriksson B, Salmela PI etal. Efficacy and safety
`of lanreotide prolonged release in patients with gastrointestinal
`neuroendocrine tumors with hormonerelated symptoms. J Clin
`Oncol 1999; 17: 1111-7.
`
`Correspondenceto:
`K. Oberg, MD, PhD
`Department of Endocrine Oncology
`Uppsala University Hospital
`$-751 85 Uppsala
`Sweden
`
`
`
`
`
`9107‘SZYouRJ|UOJuoUNIedaqs]elIagye/810's[euINo[ps0;xo'oUOUUR//:dj)}YyWOpopeojumog
`
`West-Ward Pharm.
`Exhibit 1025
`Page 004
`
`West-Ward Pharm.
`Exhibit 1025
`Page 004
`
`